Can-Fite BioPharma Ltd. (CANF) Press Releases https://ir.canfite.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/canfite/files/theme/images/logo-sm.png Can-Fite BioPharma Ltd. Logo Equisolve Investor Relations Suite <![CDATA[Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer]]> https://ir.canfite.com/news-events/press-releases/detail/1123/can-fite-namodenoson-enhances-the-anti-cancer-effect-of Mon, 17 Aug 26 07:00:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1123/can-fite-namodenoson-enhances-the-anti-cancer-effect-of <![CDATA[Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates]]> https://ir.canfite.com/news-events/press-releases/detail/1122/can-fite-highlights-advanced-fda-and-ema-regulatory-status Wed, 12 Aug 26 07:00:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1122/can-fite-highlights-advanced-fda-and-ema-regulatory-status <![CDATA[Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome]]> https://ir.canfite.com/news-events/press-releases/detail/1121/can-fite-launches-first-clinical-program-for-piclidenoson Mon, 03 Aug 26 07:00:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1121/can-fite-launches-first-clinical-program-for-piclidenoson <![CDATA[Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology]]> https://ir.canfite.com/news-events/press-releases/detail/1120/can-fite-positive-phase-2a-pancreatic-cancer-study-data Mon, 20 Jul 26 07:00:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1120/can-fite-positive-phase-2a-pancreatic-cancer-study-data <![CDATA[Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer]]> https://ir.canfite.com/news-events/press-releases/detail/1119/can-fite-secures-australian-patent-allowance-supporting Tue, 14 Jul 26 07:00:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1119/can-fite-secures-australian-patent-allowance-supporting <![CDATA[Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027]]> https://ir.canfite.com/news-events/press-releases/detail/1118/can-fite-achieves-key-pivotal-phase-3-psoriasis-milestone Mon, 06 Jul 26 07:00:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1118/can-fite-achieves-key-pivotal-phase-3-psoriasis-milestone <![CDATA[Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease]]> https://ir.canfite.com/news-events/press-releases/detail/1117/can-fite-phase-2a-pancreatic-cancer-study-with-namodenoson Wed, 01 Jul 26 07:00:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1117/can-fite-phase-2a-pancreatic-cancer-study-with-namodenoson <![CDATA[Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology]]> https://ir.canfite.com/news-events/press-releases/detail/1116/can-fite-secures-japanese-patent-allowance-for Fri, 26 Jun 26 07:00:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1116/can-fite-secures-japanese-patent-allowance-for <![CDATA[Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson]]> https://ir.canfite.com/news-events/press-releases/detail/1115/can-fite-publishes-peer-reviewed-scientific-article Mon, 22 Jun 26 07:00:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1115/can-fite-publishes-peer-reviewed-scientific-article <![CDATA[Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026]]> https://ir.canfite.com/news-events/press-releases/detail/1114/can-fite-to-present-late-stage-clinical-pipeline-and Wed, 17 Jun 26 07:00:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1114/can-fite-to-present-late-stage-clinical-pipeline-and